Nunzio Pomara1, Sang Han Lee2, Davide Bruno3, Timothy Silber4, David J Greenblatt5, Eva Petkova6, John J Sidtis6. 1. Nathan Kline Institute, Orangeburg, NY, USA; New York University School of Medicine, New York, NY, USA. Electronic address: pomara@nki.rfmh.org. 2. Nathan Kline Institute, Orangeburg, NY, USA. 3. Nathan Kline Institute, Orangeburg, NY, USA; New York University School of Medicine, New York, NY, USA; Liverpool Hope University, Liverpool, UK. 4. Nathan Kline Institute, Orangeburg, NY, USA; Washington University in St. Louis, St. Louis, MO, USA. 5. Tufts University School of Medicine, Boston, MA, USA. 6. Nathan Kline Institute, Orangeburg, NY, USA; New York University School of Medicine, New York, NY, USA.
Abstract
BACKGROUND: The benzodiazepine lorazepam is widely utilized in the treatment of elderly individuals with anxiety disorders and related conditions. Negative effects of acute lorazepam administration on cognitive performance, especially memory, have been reported in both previously untreated elderly and in individuals who have received short term (up to three weeks) treatment with therapeutic doses. However, it remains unclear if these adverse cognitive effects also persist after long-term use, which is frequently found in clinical practice. METHODS:Cognitively intact elderly individuals (n=37) on long-term (at least three months) daily treatment with lorazepam were studied using a double-blind placebo-controlled cross-over study design. Subjects were administered their highest daily unit dose of lorazepam (0.25-3.00 mg) or placebo on different days, approximately 1 week apart in a random order, and were assessed on memory, psychomotor speed, and subjective mood states. RESULTS: Subjects had significantly poorer recall and slowed psychomotor performance following acute lorazepam administration. There were no significant effects on self-ratings of mood, sedation, or anxiety in the whole group, but secondary analyses suggested a differential response in subjects with Generalized Anxiety Disorder. CONCLUSIONS: The reduced recall and psychomotor slowing that we observed, along with an absence of significant therapeutic benefits, following acute lorazepam administration in elderly long-term users reinforces the importance of cognitive toxicity as a clinical factor in benzodiazepine use, especially in this population.
RCT Entities:
BACKGROUND: The benzodiazepinelorazepam is widely utilized in the treatment of elderly individuals with anxiety disorders and related conditions. Negative effects of acute lorazepam administration on cognitive performance, especially memory, have been reported in both previously untreated elderly and in individuals who have received short term (up to three weeks) treatment with therapeutic doses. However, it remains unclear if these adverse cognitive effects also persist after long-term use, which is frequently found in clinical practice. METHODS: Cognitively intact elderly individuals (n=37) on long-term (at least three months) daily treatment with lorazepam were studied using a double-blind placebo-controlled cross-over study design. Subjects were administered their highest daily unit dose of lorazepam (0.25-3.00 mg) or placebo on different days, approximately 1 week apart in a random order, and were assessed on memory, psychomotor speed, and subjective mood states. RESULTS: Subjects had significantly poorer recall and slowed psychomotor performance following acute lorazepam administration. There were no significant effects on self-ratings of mood, sedation, or anxiety in the whole group, but secondary analyses suggested a differential response in subjects with Generalized Anxiety Disorder. CONCLUSIONS: The reduced recall and psychomotor slowing that we observed, along with an absence of significant therapeutic benefits, following acute lorazepam administration in elderly long-term users reinforces the importance of cognitive toxicity as a clinical factor in benzodiazepine use, especially in this population.
Authors: R J Bertz; P D Kroboth; F J Kroboth; I J Reynolds; F Salek; C E Wright; R B Smith Journal: J Pharmacol Exp Ther Date: 1997-06 Impact factor: 4.030
Authors: Lauren M Reynolds; Elif Engin; Gabriella Tantillo; Hew Mun Lau; John W Muschamp; William A Carlezon; Uwe Rudolph Journal: Neuropsychopharmacology Date: 2012-07-04 Impact factor: 7.853
Authors: Tija C Jacob; Guido Michels; Liliya Silayeva; Julia Haydon; Francesca Succol; Stephen J Moss Journal: Proc Natl Acad Sci U S A Date: 2012-10-22 Impact factor: 11.205
Authors: Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte Journal: J Occup Environ Med Date: 2017-11 Impact factor: 2.162
Authors: Patrick G Lyons; Ashley Snyder; Sarah Sokol; Dana P Edelson; Babak Mokhlesi; Matthew M Churpek Journal: J Hosp Med Date: 2017-06 Impact factor: 2.960